Surmodics, Inc.

NASDAQ: SRDX    
Share price (5/17/24): $34.62    
Market cap (5/17/24): $494 million
Search in Documents
Key Exhibits
External Links
3 Surmodics, Inc. Expert Interviews, now on BamSEC.
 Powered by Tegus.

Material Contracts Filter

EX-10
from 10-Q 51 pages Fifth Addendum to Lease
12/34/56
EX-10.1
from 8-K 154 pages Certain Information Contained in This Document Has Been Omitted Either Because It Is Not Material or Is the Type That the Registrant Treats as Private or Confidential. Omitted Portions Are Marked With [****] in This Exhibit. the Registrant Agrees to Furnish Any Omitted Schedule (Or Similar Attachments) to the Securities and Exchange Commission Upon Request
12/34/56
EX-10.1
from 10-Q 45 pages Fourth Addendum to Lease
12/34/56
EX-10.27
from 10-K 2 pages Board Compensation Policy Surmodics, Inc
12/34/56
EX-10.32
from 10-K 3 pages Surmodics, Inc. 2019 Equity Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.1
from 10-Q 7 pages Form of Change of Control Agreement
12/34/56
EX-10.1
from 10-Q 2 pages Board Compensation Policy
12/34/56
EX-10.6
from 8-K 4 pages Surmodics, Inc. 2019 Equity Incentive Plan Deferred Stock Unit Master Agreement
12/34/56
EX-10.5
from 8-K 3 pages Surmodics, Inc. 2019 Equity Incentive Plan Restricted Stock Unit Award Agreement Terms and Conditions
12/34/56
EX-10.4
from 8-K 4 pages Surmodics, Inc. 2019 Equity Incentive Plan Performance Stock Unit Award Agreement
12/34/56
EX-10.3
from 8-K 3 pages Surmodics, Inc. 2019 Equity Incentive Plan Restricted Stock Unit Award Agreement Terms and Conditions
12/34/56
EX-10.2
from 8-K 5 pages Surmodics, Inc. 2019 Equity Incentive Plan Restricted Stock Award Agreement
12/34/56
EX-10.1
from 8-K 4 pages Surmodics, Inc. 2019 Equity Incentive Plan Non-Qualified Stock Option Award Agreement
12/34/56
EX-10.34
from 10-K 12 pages Change of Control Agreement
12/34/56
EX-10.2
from 10-Q 87 pages Development and Distribution Agreement Between Surmodics, Inc. and Abbott Vascular, Inc. Dated as of February 26, 2018
12/34/56
EX-10.1
from 8-K 12 pages Change of Control Agreement
12/34/56
EX-10.17
from 10-K 2 pages Material contract
12/34/56
EX-10.1
from 10-Q 3 pages Via Email and U.S. Mail Surmodics, Inc. 9924 West 74th Street Eden Prairie, Mn 55344 Attn: Andrew D.C. Lafrence Re: Letter Regarding EBITDA Dear Andy
12/34/56
EX-10.18
from 10-K 2 pages Board Compensation Policy Surmodics, Inc
12/34/56
EX-10.3
from 10-Q 6 pages Law Society of Ireland General Conditions of Sale 2009 Edition Particulars and Conditions of Sale Of
12/34/56